In Response to: Corticosteroids in Non-severe COVID-19: Finding Window of Opportunity

Prashant Nasa^{1https://orcid.org/0000-0003-1948-4060}, Dhruva Chaudhry^{2https://orcid.org/0000-0001-5138-2908}

¹Department of Critical Care Medicine, NMC Specialty Hospital, Dubai, United Arab Emirates

²Department of Pulmonary and Critical Care, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India

Corresponding Author: Prashant Nasa, Department of Critical Care Medicine, NMC Specialty Hospital, Dubai, United Arab Emirates, Phone: +971501425022, e-mail: dr.prashantnasa@hotmail.com

How to cite this article: Nasa P, Chaudhry D. In Response to: Corticosteroids in Non-severe COVID-19: Finding Window of Opportunity. Indian J Crit Care 2022;26(3):405.

Source of support: Nil

Conflict of interest: None

Keywords: Acute respiratory distress syndrome, Corticosteroids, Coronavirus disease-2019, Severe acute respiratory syndrome coronavirus 2.

Sir,

We appreciate the intuitive comments from our colleagues regarding our article on expert consensus statements on the use of corticosteroids in non-severe coronavirus disease-2019 (COVID-19).¹ The experts in this Delphi were against the non-selective use of corticosteroids for mild and moderate COVID-19 without evidence of disease progression. However, the dogma of severe vs non-severe COVID-19 in determining the use of corticosteroids should be appraised in light of the clinical findings and pathophysiology of COVID-19.

Inflammation is the cornerstone to the pathogenesis of COVID-19-related lung injury.² With their immunomodulatory properties, corticosteroids are a potent therapeutic in managing COVID-19. World Health Organization (WHO) living guidelines recommended no corticosteroid for managing non-severe COVID-19 with a conditional or weak recommendation.³ This recommendation was based on a subgroup analysis of an unblinded RECOVERY trial which found an increased risk of 28-day mortality [odd ratio 1.22 (95% CI 0.93–1.61)] with systemic corticosteroids in patients without oxygen.⁴ WHO also recommended considering corticosteroids if clinical condition worsens in non-severe COVID-19.³ Hence, in the ambiguity of the clinical evidence, consensus statements among a panel of experts were developed using a Delphi approach.⁵

Once the hypoxemia sets in, the delay in the initiation of corticosteroids may worsen the outcome. Predicting the disease progression needs an astute clinical assessment and combination of biochemical and imaging criteria.^6,7 We do not recommend a single biochemical or radiological test over clinical assessment for prediction of clinical progression.

We appreciate the concern raised by the colleagues on the use of corticosteroids and the risk of COVID-19-associated mucormycosis (CAM). There are multiple reasons for invasive fungal infection with COVID-19. Diabetes mellitus (DM), irrational (prolonged or high dose) corticosteroids, and COVID-19 per se are proposed risk factors for CAM. Uncontrolled hyperglycemia vs controlled DM is a significant risk factor for CAM.⁸

We recommended low-dose corticosteroids for 5–10 days with periodical blood-glucose monitoring and management. In addition, there was a recommendation on continued assessment for potential warning signs.

ORCID

Prashant Nasa https://orcid.org/0000-0003-1948-4060

Dhruva Chaudhry https://orcid.org/0000-0001-5138-2908

REFERENCES

1. Nasa P, Chaudhry D, Govil D, Daga MK, Jain R, Chhallani AA, et al. Expert consensus statements on the use of corticosteroids in non-severe COVID-19. Indian J Crit Care Med 2021;25(11):1280–1285. DOI: 10.5005/jp-journals-10071-23923.

2. Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat Med 2021;27(1):28–33. DOI: 10.1038/s41591-020-01202-8.

3. Agarwal A, Rochwerg B, Lamontagne F, Siemieniuk RA, Agoritsas T, Askie L, et al. A living WHO guideline on drugs for covid-19. British Medical Journal 2020;370:m3379. DOI: 10.1136/bmj.m3379.

4. Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with covid-19. N Engl J Med 2021;384:693–704. DOI: 10.1056/NEJMoa2021436.

5. Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J Methodol 2021;11(4):116–129. DOI: 10.5662/wjm.v11.i4.116.

6. Li J, He X, Yuan Y, Zhang W, Li X, Zhang Y, et al. Meta-analysis investigating the relationship between clinical features, outcomes, and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia. Am J Infect Control 2021;49(1):82–89. DOI: 10.1016/j.ajic.2020.06.008.

7. Ishfaq A, Yousaf Farooq SM, Goraya A, Yousaf M, Gilani SA, Kiran A, et al. Role of high resolution computed tomography chest in the diagnosis and evaluation of COVID-19 patients: a systematic review and meta-analysis. Eur J Radiol Open 2021;8:100350. DOI: 10.1016/j.ejro.2021.100350.

8. Bhattacharyya A, Sarma P, Kaur H, Kumar S, Bhattacharyya J, Prajapat M, et al. COVID-19-associated rhino-orbital-cerebral mucormycosis: a systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol 2021;53(6):499–510. DOI: 10.4103/ijp.ijp_839_21.

________________________
© The Author(s). 2022 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.